DHR vs PFE: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Danaher Corporation · Healthcare
$174.04
+13.2% upside to fair value
Grade B
VS
Pfizer Inc. · Healthcare
$26.33
+35.4% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+35.4%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
PFE |
| Current Price |
$174.04 |
$26.33 |
| Fair Value Estimate |
$197.01 |
$35.65 |
| Upside to Fair Value |
+13.2%
|
+35.4%
|
| Market Cap |
$123.2B |
$149.8B |
| Forward P/E |
33.4x
|
19.3x
|
| EV / EBITDA |
20.3x
|
12.9x
|
| Price / Sales |
5.0x
|
2.4x
|
| Price / FCF |
23.3x
|
16.5x
|
| Revenue Growth YoY |
+3.7%
|
-1.2%
|
| Gross Margin |
60.7%
|
70.3%
|
| Operating Margin |
21.0%
|
24.7%
|
| Return on Equity |
7.1%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.3%
|
6.06%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Danaher Corporation is a diversified healthcare company focused on medical diagnostics, life sciences, and biotechnology, generating approximately $24 billion in revenue with a strong recurring revenue base of over 81%. The company benefits from a high gross margin of 60.7% and solid operating margin of 21%, supported by a seasoned management team with a proven capital allocation track record inc…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
DHR |
PFE |
| Zone Low |
$147.76 |
$26.74 |
| Zone High |
$167.46 |
$30.30 |
| In Buy Zone? |
No
|
Yes
|